Single-dose PK Study of Ceftazidime-Avibactam In Hospitalized Children Receiving Systemic Antibiotics for Nosocomial Pneumonia

NCT04040621

Last updated date
Study Location
Our Lady of the Lake Children's Health Infectious Disease
Baton Rouge, Louisiana, 70809, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Hospitalized Children With Suspected or Confirmed Nosocomial Pneumonia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
3-17 months
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study:

1. Evidence of a personally signed and dated informed consent document indicating that the subject's parent(s), legal guardian, or legally acceptable representative has been informed of all pertinent aspects of the study. As appropriate per local requirements informed assent of subjects must also be documented.

2. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

3. Male or female children age ≥3 months to <18 years at Screening:

1. Cohort 1: age 12 years to <18 years;

2. Cohort 2: age 6 years to <12 years;

3. Cohort 3: age 2 years to <6 years;

4. Cohort 4: age 3 months to <2 years (must be born ≥37 weeks gestational age).

4. Hospitalized, receiving systemic antibiotic therapy for the treatment of a suspected or confirmed HAP or VAP meeting the following criteria, and expected to require hospitalization until after the follow up evaluations are completed on Day 3 (48 hours after the end of infusion):

1. Onset of symptoms ≥48 hours after admission or <7 days after discharge from an inpatient acute or chronic care facility;

2. New or worsening infiltrate on chest X ray;

3. At least 1 of the following systemic signs prior to the initiation of treatment for Nosocomial Pneumonia:

i. Fever (temperature >38°C) or hypothermia (rectal/core temperature <35°C); ii. White blood cell (WBC) count >10,000 cells/mm3, or WBC count <4,500 cells/mm3, or >15% band forms.

d. At least 2 of the following respiratory signs or symptoms: i. A new onset of cough (or worsening of cough). ii. Production of purulent sputum or endotracheal secretions. iii. Auscultatory findings consistent with pneumonia/pulmonary consolidation (eg, rales, rhonchi, bronchial breath sounds, dullness to percussion, egophony).

iv. Dyspnea, tachypnea or hypoxemia (O2 saturation <90% or PaO2 <60 mmHg while breathing room air).

v. A need for mechanical ventilation or, for already ventilated subjects, acute changes made in the ventilator support system to enhance oxygenation, as determined by, for example arterial blood gas or worsening PaO2/FiO2.

5. Likely to survive the current illness or hospitalization.

6. Sufficient IV access (peripheral or central) to receive study drug and dedicated access for PK sampling.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


Subjects with any of the following characteristics/conditions will not be included in the
study:


1. Investigator site staff members directly involved in the conduct of the study and
their family members, site staff members otherwise supervised by the Investigator, or
subjects who are Pfizer employees, including their family members, directly involved
in the conduct of the study.


2. Participation in other studies involving investigational drug(s) within 30 days prior
to study entry and/or during study participation.


3. Other acute or chronic medical or psychiatric condition including recent (within the
past year) or active suicidal ideation or behavior or laboratory abnormality that may
increase the risk associated with study participation or investigational product
administration or may interfere with the interpretation of study results and, in the
judgment of the Investigator, would make the subject inappropriate for entry into this
study.


4. Past or current history of epilepsy or seizure disorder (excluding childhood febrile
seizures.


5. Severe renal impairment defined as creatinine clearance (CrCL) ≤30 mL/min/1.73 m2
calculated using the child's measured height (length) and serum creatinine with the
Bedside Schwartz equation (Schwartz, Munoz, et al., 2009):3 CrCL (mL/min/1.73 m2) =


6. Documented history of any hypersensitivity or allergic reaction to any β lactam
antibiotic.


7. Pregnant female subjects; breastfeeding female subjects; fertile male subjects and
female subjects of childbearing potential who are unwilling or unable to use a highly
effective method of contraception as outlined in this protocol for the duration of the
study and for at least 28 days after the last dose of CAZ AVI.


8. Acute hepatitis in the prior 6 months, a prior history of cirrhosis, acute hepatic
failure, or acute decompensation of chronic hepatic failure; and/or any of the
following blood test results, for any individual, when assessed for eligibility:


1. Bilirubin >3 × upper limit of normal (ULN), unless isolated hyperbilirubinemia is
directly related to the acute infection or due to known Gilbert's disease;


2. ALT or AST >3 × ULN values used by the laboratory performing the test. Subjects
with values >3 × ULN and <5 × ULN are eligible if this value is acute and
directly related to the infectious process being treated. This must be
documented;


3. ALP >3 × ULN. Subjects with values >3 × ULN and <5 × ULN are eligible if this
value is acute and directly related to the infectious process being treated. This
must be documented.


9. Any condition (eg, septic shock, burns, cystic fibrosis, acute hemodynamic
instability, including those conditions not responding to pressor support) that would
make the patient, in the opinion of the Investigator, unsuitable for the study (eg,
would place a patient at risk; compromise the quality of the data; or interfere with
the absorption, distribution, metabolism, or excretion of CAZ AVI).


10. Receipt of a blood or blood component or scheduled for transfusion within the PK
sampling period (eg, red blood cells, fresh frozen plasma, platelets) transfusion
during the 24 hour period before enrollment.


11. Body mass index (BMI) below the 5th percentile or above the 95th percentile for
height, age, and weight except for children <2 years of age as BMI is not considered a
screening tool for healthy weight in children under 2 years of age.


12. Treatment with ceftazidime within 12 hours of CAZ AVI administration or treatment with
ceftazidime within 24 hours of CAZ AVI administration in subjects with renal
impairment (CrCL ≤50 mL/min/1.73 m2).


13. Treatment with potent inhibitors of OAT1 and/or OAT3 (eg, probenecid, p aminohippuric
acid (PAH), or teriflunomide).

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Hospitalized Children With Suspected or Confirmed Nosocomial PneumoniaSingle-dose PK Study of Ceftazidime-Avibactam In Hospitalized Children Receiving Systemic Antibiotics for Nosocomial Pneumonia
NCT04040621
  1. Baton Rouge, Louisiana
  2. Baton Rouge, Louisiana
  3. Baton Rouge, Louisiana
  4. Cleveland, Ohio
  5. Chaidari, Athens
  6. Thessaloniki,
  7. Pune, Maharashtra
  8. Quezon City, National Capital Region,
  9. San Diego, California
  10. Aurora, Colorado
  11. Aurora, Colorado
  12. New Haven, Connecticut
  13. New Haven, Connecticut
  14. New Haven, Connecticut
  15. New Brunswick, New Jersey
  16. New Brunswick, New Jersey
  17. Albuquerque, New Mexico
  18. Albuquerque, New Mexico
  19. Albuquerque, New Mexico
  20. Wuxi, Jiangsu
  21. Chengdu, Sichuan
  22. Beijing,
  23. Tallinn,
  24. Tartu,
  25. Surat, Gujarat
  26. Brescia BS, Other
  27. Kosice,
  28. Martin,
  29. Hualien,
  30. Kaohsiung City,
  31. Taipei City,
  32. Taipei,
  33. Taipei,
  34. Taipei,
  35. Taipei,
  36. Taoyuan,
ALL GENDERS
3 Months+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Single-dose PK Study of Ceftazidime-Avibactam In Hospitalized Children Receiving Systemic Antibiotics for Nosocomial Pneumonia
Official Title  ICMJE A PHASE 1, OPEN-LABEL, SINGLE-DOSE STUDY TO ASSESS THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF CEFTAZIDIME-AVIBACTAM (CAZ-AVI) IN CHILDREN FROM 3 MONTHS TO LESS THAN 18 YEARS OF AGE WHO ARE HOSPITALIZED AND RECEIVING SYSTEMIC ANTIBIOTIC THERAPY FOR SUSPECTED OR CONFIRMED NOSOCOMIAL PNEUMONIA, INCLUDING VENTILATOR-ASSOCIATED PNEUMONIA
Brief Summary This is a multicenter, multinational, open label single dose pharmacokinetic (PK) study enrolling at least 32 subjects. The study aims to characterize the pharmacokinetics (PK) of a single intravenous dose of CAZ AVI in pediatric subjects aged 3 months to less than 18 years who are receiving systemic antibiotic therapy for suspected or confirmed nosocomial pneumonia, including ventilator associated pneumonia.
Detailed Description This is a multicenter, multinational, open label single dose pharmacokinetic (PK) study enrolling at least 32 subjects. The study aims to characterize the PK of CAZ AVI and assess its safety and tolerability following a single intravenous (IV) infusion. Subjects will be hospitalized pediatric patients who are receiving systemic antibiotic therapy for suspected or confirmed nosocomial pneumonia (NP), including ventilator associated pneumonia (VAP). The study will consist of a Screening visit (Visit 1, Day 1), during which consent will be obtained and subject eligibility will be confirmed, a Baseline/Treatment visit (Visit 2, Day 1) during which subjects will receive a single IV infusion of CAZ AVI, and then two follow up assessment visits at 24 hours (Visit 3, Day 2) and 48 hours (Visit 4, Day 3). Blood samples for PK analyses (0.5 mL per sample) will be obtained over 22 hours for Cohort 1 (7 samples), over 13 hours for Cohort 2 (6 samples), and over 6 hours for Cohorts 3 and 4 (4 samples). Additionally, for subjects who are undergoing bronchoalveolar lavage (BAL) for clinical purposes and for whom informed consent is obtained specifically for BAL, an epithelial lining fluid (ELF) sample will be collected for estimation of CAZ AVI concentrations.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description:
Non-randomized, single arm
Masking: None (Open Label)
Primary Purpose: Basic Science
Condition  ICMJE Hospitalized Children With Suspected or Confirmed Nosocomial Pneumonia
Intervention  ICMJE Drug: Ceftazidime-avibactam
Single intravenous infusion of ceftazidime-avibactam over 2 hours. Dosage will vary depending upon age, weight and renal function.
Study Arms  ICMJE Experimental: Ceftazidime-avibactam
This arm includes 4 cohorts
Intervention: Drug: Ceftazidime-avibactam
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: July 30, 2019)
32
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE November 12, 2021
Estimated Primary Completion Date November 12, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study:

  1. Evidence of a personally signed and dated informed consent document indicating that the subject's parent(s), legal guardian, or legally acceptable representative has been informed of all pertinent aspects of the study. As appropriate per local requirements informed assent of subjects must also be documented.
  2. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
  3. Male or female children age ?3 months to <18 years at Screening:

    1. Cohort 1: age 12 years to <18 years;
    2. Cohort 2: age 6 years to <12 years;
    3. Cohort 3: age 2 years to <6 years;
    4. Cohort 4: age 3 months to <2 years (must be born ?37 weeks gestational age).
  4. Hospitalized, receiving systemic antibiotic therapy for the treatment of a suspected or confirmed HAP or VAP meeting the following criteria, and expected to require hospitalization until after the follow up evaluations are completed on Day 3 (48 hours after the end of infusion):

    1. Onset of symptoms ?48 hours after admission or <7 days after discharge from an inpatient acute or chronic care facility;
    2. New or worsening infiltrate on chest X ray;
    3. At least 1 of the following systemic signs prior to the initiation of treatment for Nosocomial Pneumonia:

    i. Fever (temperature >38°C) or hypothermia (rectal/core temperature <35°C); ii. White blood cell (WBC) count >10,000 cells/mm3, or WBC count <4,500 cells/mm3, or >15% band forms.

    d. At least 2 of the following respiratory signs or symptoms: i. A new onset of cough (or worsening of cough). ii. Production of purulent sputum or endotracheal secretions. iii. Auscultatory findings consistent with pneumonia/pulmonary consolidation (eg, rales, rhonchi, bronchial breath sounds, dullness to percussion, egophony).

    iv. Dyspnea, tachypnea or hypoxemia (O2 saturation <90% or PaO2 <60 mmHg while breathing room air).

    v. A need for mechanical ventilation or, for already ventilated subjects, acute changes made in the ventilator support system to enhance oxygenation, as determined by, for example arterial blood gas or worsening PaO2/FiO2.

  5. Likely to survive the current illness or hospitalization.
  6. Sufficient IV access (peripheral or central) to receive study drug and dedicated access for PK sampling.

Exclusion Criteria:

Subjects with any of the following characteristics/conditions will not be included in the study:

  1. Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the Investigator, or subjects who are Pfizer employees, including their family members, directly involved in the conduct of the study.
  2. Participation in other studies involving investigational drug(s) within 30 days prior to study entry and/or during study participation.
  3. Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the subject inappropriate for entry into this study.
  4. Past or current history of epilepsy or seizure disorder (excluding childhood febrile seizures.
  5. Severe renal impairment defined as creatinine clearance (CrCL) ?30 mL/min/1.73 m2 calculated using the child's measured height (length) and serum creatinine with the Bedside Schwartz equation (Schwartz, Munoz, et al., 2009):3 CrCL (mL/min/1.73 m2) =
  6. Documented history of any hypersensitivity or allergic reaction to any ? lactam antibiotic.
  7. Pregnant female subjects; breastfeeding female subjects; fertile male subjects and female subjects of childbearing potential who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 28 days after the last dose of CAZ AVI.
  8. Acute hepatitis in the prior 6 months, a prior history of cirrhosis, acute hepatic failure, or acute decompensation of chronic hepatic failure; and/or any of the following blood test results, for any individual, when assessed for eligibility:

    1. Bilirubin >3 × upper limit of normal (ULN), unless isolated hyperbilirubinemia is directly related to the acute infection or due to known Gilbert's disease;
    2. ALT or AST >3 × ULN values used by the laboratory performing the test. Subjects with values >3 × ULN and <5 × ULN are eligible if this value is acute and directly related to the infectious process being treated. This must be documented;
    3. ALP >3 × ULN. Subjects with values >3 × ULN and <5 × ULN are eligible if this value is acute and directly related to the infectious process being treated. This must be documented.
  9. Any condition (eg, septic shock, burns, cystic fibrosis, acute hemodynamic instability, including those conditions not responding to pressor support) that would make the patient, in the opinion of the Investigator, unsuitable for the study (eg, would place a patient at risk; compromise the quality of the data; or interfere with the absorption, distribution, metabolism, or excretion of CAZ AVI).
  10. Receipt of a blood or blood component or scheduled for transfusion within the PK sampling period (eg, red blood cells, fresh frozen plasma, platelets) transfusion during the 24 hour period before enrollment.
  11. Body mass index (BMI) below the 5th percentile or above the 95th percentile for height, age, and weight except for children <2 years of age as BMI is not considered a screening tool for healthy weight in children under 2 years of age.
  12. Treatment with ceftazidime within 12 hours of CAZ AVI administration or treatment with ceftazidime within 24 hours of CAZ AVI administration in subjects with renal impairment (CrCL ?50 mL/min/1.73 m2).
  13. Treatment with potent inhibitors of OAT1 and/or OAT3 (eg, probenecid, p aminohippuric acid (PAH), or teriflunomide).
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 3 Months to 17 Years   (Child)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Pfizer CT.gov Call Center1-800-718-1021[email protected]
Listed Location Countries  ICMJE China,   Estonia,   Greece,   India,   Italy,   Philippines,   Slovakia,   Taiwan,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04040621
Other Study ID Numbers  ICMJE C3591025
2018-002841-12 ( EudraCT Number )
EMBA ( Other Identifier: Alias Study Number )
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD:No
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Allergan
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date October 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP